RxDoctor Payments Data

Jeffrey Osborn, MD

Cardiovascular Disease · Salt Lake City, UTNPI 1043288368

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 60.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $27,283 and has fallen 87.8% since, to $3,319 in 2025. Among cardiovascular disease clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$69,439in general payments, 2019–2025

Across 209 payments — averaging $332.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$42K
  • Merit Medical Systems Inc$11K
  • Medtronic$8K
  • Philips North America LLC$6K
  • Boston Scientific$3K
  • Impulse Dynamics (USA) Inc.$77
  • plus $46 from 2 others
$22,262in research payments, 2019–2025

Across 14 payments — averaging $1590.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$13K
  • Abbott$10K

What the payments were for

  • Consulting fees$37,69654%
  • Speaking & faculty fees$1,6502%
  • Travel & lodging$23,79134%
  • Food & beverage$6,3019%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,439 in reported general payments places this provider in the 95th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$186,042
Medicare patients
1,638
Services billed
4,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$304,745
XareltoRivaroxaban22$32,166
Flecainide Acetate171$7,687
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,642
Metoprolol Succinate208$3,243
Amiodarone Hcl132$2,267
Diltiazem 24hr Er (Cd)Diltiazem Hcl30$1,033
Digoxin29$729
SotalolSotalol Hcl26$471
Carvedilol25$302
Metoprolol Tartrate31$275
Warfarin Sodium11$202

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →